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How effective are current dietary guidelines for cardiovascular
disease prevention in healthy middle-aged and older men and
women? A randomized controlled trial1–4
Dianne P Reidlinger, Julia Darzi, Wendy L Hall, Paul T Seed, Philip J Chowienczyk, and Thomas AB Sanders on behalf of
the Cardiovascular disease risk REduction Study (CRESSIDA) investigators
ABSTRACT
Background: Controversy surrounds the effectiveness of dietary
guidelines for cardiovascular disease (CVD) prevention in healthy
middle-aged and older men and women.
Objective: The objective was to compare effects on vascular and
lipid CVD risk factors of following the United Kingdom dietary
guidelines with a traditional British diet (control).
Design: With the use of a parallel-designed randomized controlled trial
in 165 healthy nonsmoking men and women (aged 40–70 y), we mea-
sured ambulatory blood pressure (BP) on 5 occasions, vascular function,
and CVD risk factors at baseline and during 12 wk after random as-
signment to treatment. The primary outcomes were differences between
treatments in daytime ambulatory systolic BP, flow-mediated dilation,
and total cholesterol/HDL cholesterol. Secondary outcomes were
differences between treatment in carotid-to-femoral pulse wave velocity,
high-sensitivity C-reactive protein, and a measure of insulin sensitivity
(Revised Quantitative Insulin Sensitivity Check Index).
Results: Data were available on 162 participants, and adherence to the
dietary advice was confirmed from dietary records and biomarkers of com-
pliance. In the dietary guidelines group (n = 80) compared with control (n =
82), daytime systolic BP was 4.2 mm Hg (95% CI: 1.7, 6.6 mm Hg; P ,
0.001) lower, the treatment effect on flow-mediated dilation [20.62% (95%
CI:21.48%, 0.24%)] was not significant, the total cholesterol:HDL choles-
terol ratio was 0.13 (95% CI: 0, 0.26; P = 0.044) lower, pulse wave velocity
was 0.29 m/s (95% CI: 0.07, 0.52 m/s; P = 0.011) lower, high-sensitivity C-
reactive protein was 36% (95% CI: 7%, 48%; P = 0.017) lower, the treat-
ment effect on the Revised Quantitative Insulin Sensitivity Check Index [2%
(95%CI:22%, 5%)] was not significant, and body weight was 1.9 kg (95%
CI: 1.3, 2.5 kg; P, 0.001) lower. Causal mediated effects analysis based on
urinary sodium excretion indicated that sodium reduction explained 2.4 mm
Hg (95% CI: 1.0, 3.9 mm Hg) of the fall in blood pressure.
Conclusion: Selecting a diet consistent with current dietary guide-
lines lowers BP and lipids, which would be expected to reduce
the risk of CVD by one-third in healthy middle-aged and older
men and women. This study is registered at www.isrctn.com as
92382106. Am J Clin Nutr 2015;101:922–30.
Keywords: blood pressure, endothelial function, lipids, arterial
stiffness, dietary pattern
INTRODUCTION
Population-based strategies to prevent cardiovascular disease
(CVD)5 focus on diet and lifestyle modification (1). There is general
agreement regarding smoking cessation and prevention of obesity,
but reductions in sodium intake (2) in normotensive persons and the
replacement of SFAs with n–6 PUFAs (3, 4) remain contentious.
Cohort studies suggest that the replacement of SFAs with carbohy-
drates, especially refined carbohydrates (5), but not those with a low
glycemic index, particularly those from whole grains (6), might in-
crease CVD risk or may have no effect (7). A possible explanation
may be that although some SFA–rich foods such as red and fatty
meat are associated with increased risk, others such as nuts, oily fish,
milk, and dairy foods are associated with a lower risk (8).
Dietary guidelines for CVD prevention are broadly similar in
the United Kingdom (9), Western Europe, and United States (10)
and focus on modifying the overall dietary pattern so that food
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and nutrient targets are met. Supporting evidence is derived from
observational data from prospective cohort studies as well as the
effects of individual dietary components on surrogate risk markers
[i.e., blood pressure (BP), serum cholesterol] for CVD rather than
from controlled trials with clinical endpoints. The nutrient targets
for reduced sodium (salt), added sugar, and SFA and trans fatty
acid intakes, as well as increased intakes of potassium and fiber,
have been translated to food-based guidelines: these include
replacement of fats rich in SFAs with unsaturated fatty acids
(mainly MUFAs); the selection of low-fat dairy products and
whole-grain cereals; an increased consumption of fruit, vegeta-
bles, and fish; and the avoidance of fatty meat, meat products, salt,
and added sugar. The Dietary Approaches to Stop Hypertension
(11, 12) and Optimal Macronutrient Intake Trial to Prevent Heart
Disease (13) studies demonstrated that global changes in diet
were more effective than focusing on individual components in
lowering BP in participants with mildly or moderately elevated
BP who were at above average risk of CVD. However, most CVD
events occur in those at average risk (14). The present study was
designed to test whether conforming to the United Kingdom di-
etary guidelines lowers the risk of CVD in participants judged to
be at average risk, with a particular focus on vascular function.
Key features of this study are that the participants were free living
and empowered to modify their dietary pattern, and evidence of
compliance to the intervention was provided by monitoring ob-
jective biomarkers of intake.
METHODS
Study design
CRESSIDA (Cardiovascular disease risk REduction Study),
registered at www.isrctn.com as 92382106, was a 12-wk parallel-
designed randomized controlled trial that compared United
Kingdom dietary guidelines (DGs) (15) with a control diet based
on a traditional British dietary pattern. The study was approved by
the South London Research Ethics Committee (ref: 10/H0802/24).
Participants gave informed written consent and received a small
remuneration for taking part. Outcome measurements were made
at baseline and after randomization to their respective diets.
Participant selection and randomization
Nonsmoking healthy men and women [aged 40–70 y; BMI (in
kg/m2) $18.5 and #35] were recruited (August 2010–July
2012) by newspaper (London Metro) and electronic advertise-
ment (e-mail from the university and website). Respondents,
who appeared suitable from a questionnaire, attended a clinic in
the fasting state for measurement of height, weight, waist cir-
cumference, and seated BP and collection of urine and blood
samples to assess liver function, glucose, lipids, hematology, and
nonsmoking status by urinary cotinine measurement. Seated BP
was measured in triplicate at 2-min intervals after a 10-min rest
by using an upper-arm blood pressure monitor (Omron 705CP;
Omron Health Care). The first reading was discarded and the
mean for the 2 following readings taken; if the readings were
more than 10% different, further readings were obtained. Ex-
clusion criteria included diagnosis of CVD or .20% 10-y risk
of CVD by using the QRISK-2 (14), which includes age; eth-
nicity; systolic BP (SBP); total cholesterol:HDL cholesterol
ratio; BMI; angina or heart attack in a first-degree relative aged
,60 y in the algorithm; cancer (excluding basal cell carcinoma)
in the previous 5 y; diabetes mellitus; chronic renal, liver, or
inflammatory bowel disease; history of substance abuse or al-
coholism; pregnancy; or weight change of .3 kg in preceding
2 mo. Before randomization to treatment, eligible participants
were required to complete two 24-h ambulatory BP (ABP)
measurements and urine collections, a 4-d food record, and
validated food-frequency (16) and physical activity question-
naires (17). Treatment was allocated by minimization for age,
sex, ethnicity, and BMI by using a custom-designed computer
database (MedSciNet AB). Where 2 participants cohabited, both
were allocated to the same treatment group (17 couples).
Participants attended the clinical research facility at St
Thomas’ Hospital, London, United Kingdom, in the fasting state
for measurements of vascular function and to provide blood
samples; procedures were repeated after 12 wk. The mean of
the 2 preintervention 24-h ABP measurements was used as the
baseline. Three 24-h ABP measurements and urine collections
were made at wk 4–6, 8, and 12 during treatment; and a 4-d food
record and food-frequency and physical activity questionnaires
were completed toward the end of the study. The timeline for the
study is shown in Supplemental Figure 1.
Interventions and measurements
The key dietary targets for the DG diet were to reduce sodium
intake to ,100 mmol/d; to reduce total fat, saturated fatty acids,
and nonmilk extrinsic sugars to ,35%, ,11%, and ,11% en-
ergy, respectively; and to increase the consumption of oily fish
to at least 1 serving/wk, fruit and vegetables to at least 5 serv-
ings/d, and whole grains to at least 2 servings/d. These targets
were achieved by dietary advice, which aimed to ensure that
weight stability was provided by a dietitian (DR) after baseline
measurements, and reinforced by face-to-face meetings (week 4)
or by e-mail/phone call (weeks 6 and 8). Participants allocated
to DG were provided with a margarine low in SFAs (16 g/100 g)
and trans fatty acids (,0.5 g/100 g) and a liquid vegetable oil
(high-oleic sunflower oil; 9 g SFAs/100 g). They were advised to
choose low-fat dairy products and select lean cuts of meat and
to avoid meat products (ham, sausages, hamburgers), sugar-
sweetened beverages, and added salt at the table and during food
preparation. Instructions were given on interpreting food labels
to select foods with a lower salt and SFA content and on se-
lecting foods eaten outside the home.
The control diet was a nutritionally balanced traditional British
diet without restriction on salt and sugar intake. It was based
around refined cereals (white bread, pasta, breakfast cereals,
white rice) and potatoes with meat (red meat, meat products, or
poultry) but with a limited intake of oily fish (less than once
a month) and whole-grain cereals. Participants allocated to the
control diet were supplied with a butter-based spread (35.3 g
SFAs/100 g and 2.4 g trans fatty acids/100 g) and a liquid un-
hydrogenated vegetable oil (palm olein) that contained 40%
SFAs. They were advised to consume 3 servings of full-fat dairy
products (milk, yogurt, and cheese) and at least 1 serving of fruit
and 2 servings of vegetables each day.
Both groups were given advice to limit consumption of
confectionery and snack foods (chips, cake, cookies) and to
drink alcohol within safe limits. Participants were provided with
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a choice of breakfast cereals (whole grain or refined), rice (brown
or white), some snack foods (nuts/cereal bars or chocolate
cookies/crackers), and tinned fish (mackerel/sardines or tuna).
Both groups were given baked beans; the DG group received the
reduced sugar and salt product, whereas the control group re-
ceived the standard product. In addition, the DG group was
offered reduced salt condiments. Nutrient intakes were calculated
from 4-d records by using Weighed Intake analysis Software
Package (version 3.0; Tinuviel Software) before randomization
and toward the end of the intervention phase.
Compliance with the dietary advice was further verified by the
use of biomarkers of intake: 24-h urinary sodium (salt) and
potassium (fruit and vegetables) (18); sucrose and fructose ex-
cretion (added sugars) (19); the n–3 index, which is the sum
proportions of eicosapentaenoic acid and docosahexaenoic acid
in erythrocyte lipids (oily fish) (20); and plasma alkylresorcinol
concentrations (whole grains) (21). Completeness of urine col-
lection was assessed by using para-aminobenzoic acid (PABA)
(22) as well as creatinine because 3 participants declined to take
PABA.
Clinic visits
Participants abstained from alcohol and strenuous activity 24 h
before the clinic visits and were provided with a low-fat ready
meal (10 g fat, 3 MJ) to consume in the evening (before 2100) and
thus fasted overnight consuming no fluid other than water until
attending the facility between 0800 and 1000. Height, weight,
waist circumference, and seated BP were measured and a venous
blood sample collected for determination (23) of lipids, lipo-
proteins, glucose, insulin, nonesterified fatty acids, erythrocyte
lipids, high-sensitivity C-reactive protein (hsCRP), and bio-
markers of intake (18–21). After 30 min of supine rest in
a temperature-controlled room (238C), measurements were
made of supine BP in triplicate at 5-min intervals by using the
Omron 705CP device (Omron Health Care) and arterial stiffness
(23) as pulse wave velocity (PWVc-f) determined by carotid and
femoral tonometry by using a SphygmoCor VW device and
software version 7.01 (AtCor Medical Pty). Central blood
pressure was estimated from supine BP measurement and the
carotid-radial pulse wave form by using the SphygmoCor soft-
ware. After a further 15 min of supine rest, measurements
were made of endothelium-dependent and endothelium-
independent vasodilation of the brachial artery by using the
flow-mediated dilation (FMD) technique as previously described
(23), and scans were evaluated by using the Brachial Analyzer
(Medical Imaging Applications LLC). Personnel who made the
vascular and biochemical measurements were not informed of
the treatment allocation.
Outcomes
Specified primary outcomes were a 4–mm Hg change in
daytime SBP and a 5% change in the ratio of total cholesterol
(TC):HDL cholesterol as being important (24, 25) and bi-
ologically plausible and a 1% change in FMD as being clinically
significant. A sample size of 78/group had 90% power to detect
a 4–mm Hg effect of diet on daytime systolic ABP at P , 0.05,
assuming at least one useful measurement at baseline and 3 on
treatment (26). An SD of 13 and correlations between mea-
surements of 0.68 (baseline to follow-up) and 0.72 (follow-up)
were assumed on the basis of earlier data (18); the same data
suggested that a sample size of 64 was sufficient to detect
a change in FMD from 6.7% to 7.7% at P , 0.05 with 80%
power, assuming an SD of 2%. Secondary outcomes were
changes in PWVc-f, hsCRP, and insulin sensitivity by using the
Revised Quantitative Insulin Sensitivity Check Index (27).
Further analysis of 24-h urinary C-peptide excretion was con-
ducted post hoc as an indicator of insulin secretion on baseline,
midpoint, and endpoint samples. Post hoc analyses of plasma
25-hydroxyvitamin D, homocysteine, endothelin, and ferritin
were made on baseline and follow-up samples.
Statistical analysis
STATAversion 11.1 (StataCorp LP) was used for the statistical
analysis. Comparison between randomized groups was based on
an intention-to-treat basis with regression analysis. Subjects,
once randomly allocated, continued to be analyzed as far as
possible in their original randomized groups. Treatment effects
are shown as the comparisons between diets at the end of the
study adjusted for baseline values. Corrections were made by
using multiple linear regression with robust standard errors for
the baseline values and the minimization variables used in the
randomization: sex, age group (40–49, 50–59, and 60–70 y),
ethnicity (white, black, and other), and BMI group (18.5–24.9,
25–29.9, and 30.0–35.0). The intervention effect was the co-
efficient for the DG group compared with the control group in
the regression analysis. The quantiles of each variable were
plotted against the quantiles of the normal distribution, and loge
transformations were used where substantial deviations from
normality were revealed, and in these cases, the treatment effect
is shown as the percent change. The contribution of changes in
sodium intake and BMI to BP reduction was estimated by using
average causal mediated effects modeling (28).
RESULTS
Baseline characteristics of the study participants
Of 227 potential eligible participants, 165 were randomly al-
located to treatment and 162 completed the study. Reasons for
noncompletion were withdrawal of consent before receiving the
intervention, family bereavement, and unwillingness to follow
dietary advice (see Supplemental Figure 2 for the Consolidated
Standards of Reporting Trials diagram). The details of the par-
ticipants are shown in Table 1. There were more women than men,
and around one-fifth of the participants were ethnic minorities;
estimated risk of a CVD event by using QRISK-2 over the next
10 y was about 8% in the men and 4% in the women and typical
for their age group in the United Kingdom population (14).
Compliance to the dietary advice
The composition of the participants’ usual diets at baseline is
shown with both groups combined because there were no between-
group differences (Table 2). Neither food records nor physical
activity records indicated any change in energy intake or ex-
penditure following allocation to their respective diets. The
within-subject SD for measures of body weight was 1.4 kg,
indicating that weight was relatively stable. However, mean
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body weight fell by 1.3 kg (95% CI: 1.8, 0.9) in the DG group
and increased in the control group by 0.6 kg (95% CI: 0.2, 1.0)
over the 12-wk study period (Figure 1A), showing significant
treatment-associated differences in weight of 1.9 kg (95% CI:
1.3, 2.5; P , 0.001) and BMI of 0.7 (95% CI: 0.5, 0.9; P ,
0.001) in the DG compared with control group. Both diets were
well accepted and did not differ in cost. Changes in dietary
intake in the control group were minimal (except for an ad-
ditional 8 g SFAs/d) compared with their usual diet. In con-
trast, there were marked changes after DG. In the DG group
compared with the control group, protein and dietary fiber
intakes were 2.1% energy and 7.6 g/d higher, respectively;
nonmilk extrinsic sugar, fat, and SFA and trans fatty acid intakes
were 2.6%, 3.4%, 7.2%, and 0.6% energy lower, respectively,
and those of MUFAs and PUFAs were 3.4% and 1.9% higher;
the intake of long-chain n–3 PUFAs was 1.3 g/d higher; sodium
intake was 65 mmol/d lower; and potassium intake was 12
mmol/d greater.
At baseline, total fat and SFAs supplied 35% and 12% of
energy intake, respectively, and salt intakes (8 g/d) estimated
from 4-d records and 24-h urine sodium excretion were similar to
those reported in the National Diet and Nutrition Survey, a na-
tionally representative survey of men and women in the United
Kingdom population (29, 30) (Table 3). Most participants al-
located to the DG group met the target for SFAs and total fat.
Self-reported intakes of sugar from sugar-sweetened beverages
TABLE 1
Details of the study participants by randomized treatment group1
Dietary guidelines (n = 82) Control (n = 83)
Age, y 53 6 82 52 6 8
Sex, M/F, n 32/49 33/50
Postmenopausal, n (%) 25 (50%) 28 (56%)
White/black/Asian, n 71/6/5 66/10/7
BMI, kg/m2 25.5 6 3.7 26.8 6 3.9
Waist circumference, M/F, cm 98 6 10/88 6 12 97 6 12/91 6 10
Seated SBP/DBP, mm Hg 119 6 14/77 6 8 120 6 14/79 6 9
24-h SBP/DBP, mm Hg 120.4 6 12.6/73.3 6 7.1 122.7 6 13.3/74.4 6 7.0
Glucose, mmol/L 5.3 6 0.5 5.2 6 0.5
Total cholesterol, mmol/L 5.31 6 1.04 5.35 6 0.95
TC:HDL cholesterol ratio 3.5 6 1.0 3.7 6 1.0
10-y CVD risk, M/F, % 7.7 6 5.2/3.3 6 3.0 7.6 6 5.7/4.5 6 3.5
1No significant differences between groups: 2-sample test or Mann-Whitney U test. CVD, cardiovascular disease;
DBP, diastolic blood pressure; SBP, systolic blood pressure; TC, total cholesterol.
2Mean 6 SD (all such values).
TABLE 2
Nutrient intakes estimated from 4-d food diaries and BMI at baseline and changes after the DG and control diets1
Baseline (n = 162)2 DG (n = 80)3 Control (n = 82)3 Main comparison4 between groups P value5
Energy intake,6 MJ/d 9.77 6 2.08 20.18 (20.65, 0.31) 0.47 (20.2, 0.97) 20.59 (21.18, 0.01) 0.052
Physical activity level7 1.30 6 0.16 0.05 (20.02, 0.13) 20.03 (20.10, 0.05) 0.08 (20.02, 0.19) 0.125
BMI, kg/m2 26.1 6 3.9 20.4 (20.6, 20.3) 0.2 (0.1, 0.3) 20.7 (20.9, 20.5) ,0.001
Protein, % of energy 15.9 6 3.0 1.8 (1.0, 2.4) 20.2 (20.9, 0.4) 2.1 (1.3, 2.9) ,0.001
Carbohydrate, % of energy 44.9 6 7.0 0.3 (21.8, 1.1) 21.8 (23.2, 0.4) 0.5 (21.2, 2.2) 0.578
Dietary fiber, g/d 23.9 6 9.0 7.1 (5.1, 9.0) 20.2 (20.1.8, 1.5) 7.6 (5.2, 9.9) ,0.001
Sugars, % of energy 20.7 6 5.9 0.5 (21.1, 2.2) 20.6 (22.0, 0.8) 0.9 (21.1, 2.8) 0.385
NMESs, % of energy 9.8 6 4.5 22.5 (23.7, 21.4) 20.4 (21.4, 0.6) 22.6 (23.7, 21.4) ,0.001
Fat, % of energy 35.4 6 6.1 22.3 (23.8, 20.8) 2.4 (0.8, 4.0) 23.4 (25.1, 21.7) ,0.001
SFAs, % of energy 12.0 6 3.3 24.7 (25.5, 23.8) 3.2 (2.4, 4.0) 27.2 (27.9, 26.4) ,0.001
trans Fatty acids, % of energy 0.6 6 0.3 20.4 (20.4, 20.3) 0.2 (0.1, 0.3) 20.6 (20.7, 20.5) ,0.001
MUFAs, % of energy 11.8 6 2.6 3.5 (2.7, 4.4) 0.5 (20.2, 1.2) 3.3 (2.4, 4.3) ,0.001
PUFAs, % of energy 6.4 6 2.0 0.6 (0.1, 1.2) 20.8 (1.2, 20.3) 1.9 (1.3, 2.4) ,0.001
n–3 LCP, g/d 0.3 6 0.7 1.2 (0.8, 1.5) 20.3 (20.5, 20.1) 1.3 (0.9, 1.7) ,0.001
Sodium, mmol/d 139 6 53 256 (267, 245) 9 (23, 22) 265 (278, 251) ,0.001
Potassium, mmol/d 91 6 26 15 (10, 20) 1 (23, 6) 12 (7, 20) 0.009
1DG, dietary guideline; LCP, long-chain PUFAs; NMES, nonmilk extrinsic sugar.
2Means 6 SDs, no significant difference between groups at baseline.
3Mean changes from baseline; 95% CIs in parentheses.
4Mean treatment effects; 95% CIs in parentheses.
5Probability based on analysis of covariance with value on treatment regressed against the baseline value, age group, sex, ethnicity, and BMI category.
6Participants recording energy intake ,1.2 3 basal metabolic rate were excluded from estimates of energy intake: baseline DGs (n = 18), control (n =
25); follow-up DG (n = 23), control (n = 20).
7Physical activity level is the ratio of activity in relation to the resting metabolic rate.
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from the food-frequency questionnaire fell mean from a mean of
20 6 20 g/d at baseline to 10 6 12 g/d in the DG group but
remained unchanged at 21 6 20 g/d in the control group. The
4-d food records indicated a lower intake of nonmilk extrinsic
sugars, consisting mainly of added sucrose, in the DG group.
The lower urinary sucrose and fructose excretion in the DG
compared with the control group is consistent with a reduced
intake of added sugar. However, total sugar intake remained
unchanged owing to the increase in sugar intake from fruit.
Compliance with the lower sodium intake was corroborated by
a 40-mmol Na/d difference in urinary excretion, with 66% of
the DG group meeting the target of ,100 mmol/d for sodium.
Completeness of urinary collection was checked by using PABA
excretion: the mean (95% CI) recovery of PABAwas 86% (95%
CI: 83, 89) in both treatment groups, and sodium excretion was
stable in each group throughout the study (Figure 1B). At
baseline, the self-reported intakes of fruit and vegetables were
a median of 6 servings/d according to the food-frequency
questionnaire but slightly less than 5 servings/d in the 4-d food
records compared with 4 servings/d in the National Diet and
Nutritional Survey. Urinary potassium excretion was generally
high but 9 mmol/d greater in the DG group, indicating that the
participants were indeed consuming plenty of fruit and vegeta-
bles. Dietary fiber intakes were slightly greater than those in the
National Diet and Nutritional Survey (24 g/d compared with
20 g/d) at baseline. Whole-grain intake increased to 81 g/d in the
DG group compared with 32 g/d in control group and was de-
rived mainly from wheat, oats, and rice. Dietary fiber intake was
consequently 7 g/d higher, reflecting increased cereal fiber from
whole grains and corroborated by higher plasma alkylresorcinol
concentrations, which reflect intakes of whole grains mainly
from wheat, barley, and rye but not rice or oats. Oily fish intake
increased to 1.8 servings/wk, which was corroborated by an
increase in the erythrocyte n–3 index.
With regard to micronutrients (Supplemental Table 1), in-
takes of biotin. magnesium, and vitamins B-12, C, D, and E
were higher and those of vitamin A, thiamin, riboflavin, vitamin
B-6, folate, and iron were lower in men, and vitamin D and
magnesium were higher in women in the DG compared with the
control group. Serum vitamin D concentrations increased by
FIGURE 1 Mean (6SEM) changes in body weight from screening value during study (A), 24-h urinary sodium excretion (B), and daytime (C) and
nighttime (D) ambulatory SBP and DBP in participants allocated to the dietary guideline (dashed line, n = 80) or control diet (solid line, n = 82). Data were
analyzed by regression models adjusted for the baseline value, sex, and categories of age, BMI, and ethnic group. The treatment effect shown at 12 wk is
adjusted for differences in baseline values with 95% CIs. DBP, diastolic blood pressure; SBP, systolic blood pressure.
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9 nmol/L (95% CI: 4, 14; P , 0.001) and serum folate was 16%
(95% CI 7, 25; P = 0.001) lower in the DG than in the control
group; these differences could be attributed to the higher intake
of oily fish and avoidance of folic acid–fortified breakfast ce-
reals, respectively, in the DG group. However, there were no
differences between groups in serum ferritin concentrations
(25%; 95% CI: 217, 7; P = 0.43) or homocysteine concen-
tration (23.5%; 95% CI: 28.8, 1.9; P = 0.206), which are in-
dexes of iron and folate status, respectively.
Outcomes
Figure 1 shows significant falls in ambulatory SBP/diastolic
BP (DBP) of 4.2/2.5 mm Hg for daytime and 2.9/1.9 mm Hg for
nighttime in the DG compared with the control group, adjusting
for baseline values. The treatment effect for 24-h SBP/DBP (not
shown in tables or figure) included reductions (95% CIs) in mm
Hg of 3.5 (1.2, 5.7; P = 0.003)/2.2 (0.8, 3.2; P = 0.002). Clinic
supine central SBP/DBP and heart rate were 3.5 (95% CI: 1.6,
5.4; P , 0.001)/2.4 (1.1, 3.8; P , 0.001) mm Hg and 1.8 beats/
min (95% CI: 0.3, 3.3; P = 0.022) lower, respectively (Table 4).
Regression analysis adjusting for the 32% fall in sodium ex-
cretion indicated that sodium reduction explained a fall in SBP
of 2.4 mm Hg (95% CI: 1.0, 3.9), and the 0.7 decrease in BMI
suggested an explanation for a further fall of 1.1 mm Hg (95%
CI: 20.05, 2.4). PWVc-f was 0.29 m/s (95% CI: 0.07, 0.52; P =
0.011) lower, and after adjusting for central mean arterial
pressure, a difference of 0.19 m/s (95% CI: 0.10, 0.28; P ,
0.001) remained. Post hoc measurements of plasma endothelin 1
found no differences (data not shown). At baseline, 36% of
participants had FMD values ,4%, which in our laboratory is
taken to indicate impaired endothelial function. There was no
significant treatment effect on FMD, and the difference between
treatments was small (20.62%). There were no changes in
endothelium-independent vasodilation (glycerol trinitrate). Se-
rum hsCRP values were generally, low but the treatment effect
was 36% (P = 0.017) lower. TC, LDL cholesterol, apolipopro-
tein B, HDL cholesterol, apolipoprotein A, and triglycerides
were 0.46 mmol/L (8%, P , 0.001), 0.30 mmol/L (10%, P ,
0.001), 0.065 g/L (7%, P = 0.0002), 0.10 mmol/L (6%, P =
0.005), 0.043 g/L (3%, P = 0.035), and 0.12 mmol/L (9%, P =
0.027) lower, respectively. The treatment effect for the TC:HDL
cholesterol ratio was 0.13 (4%, P = 0.044) lower, paralleled by
a 0.021 (3%, P = 0.035) lower apolipoprotein B:apolipoprotein
A1 ratio. Waist circumference was 1.7 cm lower (95% CI: 0.7,
2.8; P = 0.002), but there were no significant treatment effects
on indexes of insulin sensitivity (Revised Quantitative Insulin
Sensitivity Check Index, adiponectin) or secretion (C-peptide).
DISCUSSION
The novelty of this work is that it is a randomized controlled
trial with sufficient power to evaluate the combined impact on
CVD risk of dietary guidelines compared with a typical diet in
middle-aged and older adults at average risk. Indeed, the sta-
tistically significant changes in CVD risk were in a favorable
direction with only 2 exceptions (HDL cholesterol, apolipo-
protein A1). The control diet was nutritionally balanced, besides
the slightly higher intake of saturated fat (8 g/d), but otherwise
differed little from the participants’ usual diet and generally was
not inferior in terms of micronutrient content. Consequently, the
treatment effects were almost entirely attributable to the changes
resulting from the DG diet.
TABLE 3
Comparison of dietary intakes in the participants at baseline compared with a nationally representative sample of United Kingdom adults and after
intervention in the control group and the DG groups and biomarkers of intake compared with targets1
Average United Kingdom2 Baseline3 (n = 162) Control (n = 82) DG (n = 80) Target Meeting target in DG,4 %
Total fat, % of energy 34.7 6 6.45 35.4 6 6.1 37.1 6 5.3 33.8 6 5.4 #35 57
SFA, % of energy 12.7 6 3.4 12.0 6 3.3 14.8 6 2.8 7.7 6 1.76 ,11 96
NMESs, % of energy 11.6 6 6.2 9.8 6 4.5 9.5 6 4.3 7.1 6 3.96 ,11 85
Urinary sucrose + fructose,7 mmol/24 h 43 (35, 52) 62 (49, 77) 28 (21, 37)6 ,60 76
Sodium intake, mmol/d 139 6 53 147 6 58 84 6 316 ,100 75
Sodium excretion,8 mmol/d 1329 132 6 48 142 6 58 93 6 5.46 ,100 66
Fruit and vegetables, servings/d 4 5 6 3 5 6 3 7 6 36 $5 80
Potassium excretion,8 mmol/d 87 6 26 94 6 31 83 6 216 $90 83
Whole grains, servings/d w1 1.4 6 1.1 1.0 6 1 2.7 6 1.36 .2 82
Plasma alkylresorcinols, nmol/L 69 (71, 78) 57 (47, 69) 85 (73, 98)6 .70 66
Oily fish, servings/wk ,1 1.0 6 1.0 0.2 6 0.3 1.7 6 1.56 $1 71
n–3 index, % 7.1 6 2.2 6.6 6 1.8 8.2 6 2.56 .8.0 85
180 g fruit or vegetable = 1 serving; 140 g oily fish = 1 serving; n–3 index is the sum of eicosapentaenoic acid and docosahexaenoic acid in erythrocyte
phosphoglycerides; 30 g whole grains = 1 serving. DG, dietary guideline; NMES, nonmilk extrinsic sugar.
2Data from the National Diet and Nutrition Survey (29, 30).
3No differences between groups at baseline.
4Percentage meeting target in DG group. Dietary intakes are from 4-d food records.
5Mean 6 SD (all such values).
6P , 0.01 for comparisons with the control group based on ANCOVA with value on treatment regressed against the baseline value, age group, sex,
ethnicity, and BMI category.
7Data for urinary sucrose + fructose and plasma alkylrescorcinols were loge transformed, and values are shown as geometric means; 95% CIs in
parentheses.
8Adjusted for completeness of collection by using para-amino benzoic acid recovery.
9Intake adjusted for similar proportion of men and women as in the study.
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Most remarkable was the 4.2–mm Hg fall in daytime SBP in
healthy adults achieved by following the dietary guidelines,
accompanied by falls in DBP and nighttime BP. This extends
findings in higher-risk subjects (11–13, 31) to those at average
risk of CVD. Causal mediated effects analyses indicate that
a 2.4–mm Hg change in daytime SBP could be attributed to
the reduction in sodium intake, consistent with a recent meta-
analysis (32), with a 0.7 difference in BMI possibly accounting
for a further w1 mm Hg. The falls in BP were further cor-
roborated by reductions in clinic central BP and an associated
fall in PWVc-f by w0.3 m/s. However, we found no evidence
for any change in FMD, consistent with another report (33) by
our group but in contrast to an earlier report in 29 participants
that suggested a 1.5% improvement in FMD on a low- com-
pared with high-sodium diet (34). This would argue against
a high-sodium intake having its effects on BP by decreasing
nitric oxide bioavailability. Risk estimates from a meta-analysis
of prospective cohort studies (25) suggest that a 4.2–mm Hg
lower daytime ambulatory SBP would decrease the risk of fatal
stroke and ischemic heart disease by 54% and 39%, respectively,
depending on age.
The 0.46-mmol/L (8%) reduction in serum TC and the 10%,
7%, 6%, and 3% lower LDL cholesterol, apolipoprotein B,
HDL cholesterol, and apolipoprotein A1 concentrations, re-
spectively, agree with predictions from metabolic feeding
studies of dietary fat modification (35). However, the 0.30-
mmol/L reduction in LDL cholesterol is greater than that
achieved in most community-based studies of dietary advice
(36) in which the mean reduction is 0.16 mmol/L. Our advice
was probably effective because it targeted the main source of
variability in fat intake (fatty meat, butter fat, culinary oils,
cakes, and cookies), achieved by advising against consuming
fatty meat products and advocating consumption of lean meat,
fish, and poultry; reducing fat dairy products; and replacing
cakes and cookies with fruit and nuts. We also supplied cu-
linary oils and spreads high in monounsaturated fat. The 9%
lower fasting triglyceride concentration is likely to have
resulted from reduced triglyceride synthesis in the liver
brought about by the higher intake of long-chain n–3 PUFAs
from oily fish, which inhibit triglyceride synthesis in the liver,
as well as the lower intake of sucrose and fructose, which
promote hepatic triglyceride synthesis.
TABLE 4
Changes in indexes of vascular function and lipids and indexes of insulin secretion and sensitivity after randomization to DG and control diets1
Baseline Follow-up
Main comparison between
groups2 P value3DG (n = 82) Control (n = 83) DG (n = 80) Control (n = 82)
Vascular function
FMD,4 % 5.61 6 3.005 5.33 6 3.24 4.94 6 2.54 5.44 6 3.30 20.62 (21.48, 0.24) 0.16
GTN,6 % 11.27 6 4.83 10.63 6 4.94 11.78 6 5.63 10.98 6 4.24 0.17 (21.20, 1.53) 0.80
Supine central SBP, mm Hg 109.1 6 13.8 109.9 6 12.4 105.0 6 11.6 109.4 6 12.4 23.5 (25.4, 21.6) ,0.001
Supine central DBP, mm Hg 75.1 6 8.1 75.7 6 8.5 72.2 6 7.6 75.5 6 8.8 22.4 (23.8, 21.1) 0.001
Supine heart rate, beats/min 57.5 6 7.4 57.1 6 8.3 55.2 6 7.7 57.8 6 9.2 21.8 (23.3, 20.3) 0.022
PWVc-f, m/s 7.65 6 1.31 7.39 6 1.09 7.43 6 1.22 7.61 6 1.14 20.29 (20.52, 20.07) 0.011
hsCRP,7 mg/dL 0.7 (0.3, 1.9) 1.0 (0.3, 2.1) 0.5 (0.2, 1.7) 1.3 (0.6, 2.4) 236% (248, 27) 0.017
Serum lipids
Total cholesterol, mmol/L 5.33 6 1.11 5.35 6 0.86 5.06 6 0.93 5.49 6 0.89 20.46 (20.64, 20.28) ,0.0001
LDL cholesterol, mmol/L 3.18 6 0.89 3.18 6 0.77 3.00 6 0.75 3.29 6 0.78 20.30 (20.43, 20.17) ,0.0001
Apo B, g/L 0.96 6 0.25 0.99 6 0.22 0.92 6 0.21 1.00 6 0.22 0.065 (20.098, 20.032) 0.0002
HDL cholesterol, mmol/L 1.61 6 0.40 1.56 6 0.42 1.58 6 0.38 1.62 6 0.44 20.10 (20.17, 20.03) 0.005
Apo A-I, g/L 1.57 6 0.31 1.55 6 0.30 1.55 6 0.33 1.57 6 0.30 20.043 (20.090, 20) 0.035
Triglycerides, mmol/L 1.24 6 0.59 1.33 6 0.58 1.06 6 0.45 1.23 6 0.55 20.12 (20.23, 20.01) 0.027
Total cholesterol:HDL cholesterol ratio 3.46 6 0.91 3.63 6 0.98 3.31 6 0.87 3.59 6 0.96 20.13 (20.26, 20.00) 0.044
Apo B:apoA-I ratio 0.626 6 0.171 0.649 6 0.155 0.609 6 0.163 0.651 6 0.158 20.021 (20.041, 20.001) 0.035
Indexes of insulin sensitivity
Waist, cm 91.3 6 12.2 94.1 6 11.3 90.6 6 11.9 95.2 6 11.7 21.7 (22.8, 20.7) 0.002
Fasting insulin, mU/L 6.6 6 4.2 8.5 6 6.3 7.2 6 4.8 8.0 6 5.6 9.6% (221.6, 21.5) 0.120
Urinary C-peptide, nmol/mmol creatinine 1.97 6 1.13 2.10 6 1.17 2.12 6 1.19 2.05 6 1.04 23.5% (211.3, 4.3) 0.379
Plasma glucose, mmol/L 5.33 6 0.51 5.21 6 0.44 5.31 6 0.20) 5.20 6 0.44 21% (23, 1) 0.397
Plasma NEFAs, mmol/L 0.46 6 0.18 0.45 6 0.18 0.49 6 0.18 0.49 6 0.18 21% (212, 10) 0.757
RQUICKI 0.432 6 0.069 0.419 6 0.064 0.419 6 0.056 0.415 6 0.062 2% (22, 5) 0.286
Serum adiponectin, mg/L 13.5 6 7.2 12.6 6 7.7 13.7 6 6.7 12.3 6 7.0 24% (211, 13) 0.514
1apo, apolipoprotein; DBP, diastolic blood pressure; DG, dietary guideline; FMD, flow-mediated endothelium-dependent dilation; GTN, glycerol
trinitrate–mediated endothelium-independent dilation; hsCRP, high-sensitivity C-reactive protein; NEFA, nonesterified fatty acid; PWVc-f, carotid-to-femoral
pulse wave velocity; RQUICKI, Revised Quantitative Insulin Sensitivity Check Index; SBP, systolic blood pressure.
2 Values are means; 95% CIs in parentheses.
3Probability based on analysis of covariance with value on treatment regressed against the baseline value, age group, sex, ethnicity, and BMI category.
Where the treatment effect is shown as percent change, the data were loge transformed before analysis.
4DG (n = 73), control (n = 76).
5Mean 6 SD (all such values).
6DG (n = 72), control (n = 76).
7Median (IQR), DG (n = 69), control (n = 69); values .5 mg/L were excluded.
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The 0.13 (4%) reduction in the TC:HDL cholesterol ratio and
the corresponding reduction in the apolipoprotein B:apolipo-
protein A1 ratio agree with the 0.12 reduction in TC/HDL
cholesterol observed in the 24-wk Reading Imperial Surrey
King’s study, which examined the replacement of SFAs with
MUFAs in participants with features of the metabolic syndrome
(37). The change in the TC:HDL cholesterol ratio is modest
compared with drugs such as statins. The higher SFA intake
slightly increased HDL cholesterol and apolipoprotein A1 in
addition to increasing LDL cholesterol and apolipoprotein B.
There is, however, some debate as to whether the TC:HDL
cholesterol ratio should be the touchstone for estimating lipid-
related CVD risk, because changes in HDL cholesterol do not
seem to affect risk (38), or whether LDL cholesterol should be
the primary risk indicator. However, risk estimates for the lipid
changes from prospective cohort studies using either the TC:
HDL cholesterol ratio (24) or LDL cholesterol (39) indicate
similar risk reductions of fatal and nonfatal CHD of 3% and 6%,
respectively. Mean SFA intakes in the United States (10) and
United Kingdom (29) have fallen markedly over the past few
decades to a range of 11–13% of energy, owing in part to the
replacement of animal fats and partially hydrogenated vegetable
oils with unhydrogenated vegetable oils in the food supply.
Meeting the target of ,11% of energy is likely to have a more
modest effect on TC:HDL cholesterol or LDL cholesterol than
reported here.
Despite the fall in added sugar intake, total sugar intake was
unaffected because the added sugars were replaced by sugar
supplied by fruit. In this study, we were unable to show any
effects on insulin secretion as measured by 24-h urinary C-
peptide excretion or on indexes of insulin sensitivity. A low intake
of sugar-sweetened beverages and a high intake of whole grains
are associated with a lower BMI (10) and lower hsCRP con-
centrations (40). Two recent trials of whole grains found no effect
on C-reactive protein (41, 42), but a recent Finnish study (43)
showed a fall in C-reactive protein after advice to consumewhole
grains, fish, and berries. We noted a treatment effect on hsCRP,
and this is consistent with reports of reduced hsCRP after advice
to consume fish (44) but not with long-chain n–3 PUFAs (23).
Although body weight was relatively stable over the intervention
period, we were able to detect a small but statistically significant
favorable effect on body weight and waist circumference in the
DG diet compared with the control diet, which may reflect the
greater satiating capacity of a diet rich in whole grains and fruit
and vegetables or a reduced digestibility of energy-providing
nutrients.
Strengths and weakness
The strengths of the study are as follows: it investigated the
impact of changing the whole diet rather than individual com-
ponents; it was conducted in middle-aged and older nonsmoking
men and women who were not receiving medication for BP or
hyperlipidemia, which is a strength because evidence is lacking
for prevention in populations without overt CVD or who are not
already at high risk of CVD; the participants were free living, and
the duration of intervention was longer than most previous
studies; the diet was affordable and acceptable; and there was
strong evidence of compliance with the dietary intervention and
the use of ambulatory BP monitoring. A limitation is that there
was a small change in body weight, but this may be an un-
avoidable consequence of conforming to the dietary guidelines.
The main limitation is that risk was estimated by using surrogate
markers. However, randomized controlled trials with clinical
endpoints in healthy participants are unlikely to be conducted
because of the large numbers of participants required and the
practicalities of sustaining differences in dietary intake over
several years (7). Although this diet was well received by par-
ticipants, it may be a greater challenge to bring about change in
groups who are less health conscious.
Conclusion
Selecting a diet consistent with current dietary guidelines
compared with a traditional United Kingdom dietary pattern
would be predicted on the basis of the changes in BP and lipids, to
reduce the risk of fatal and nonfatal CVD (24) by 15% and 30%,
respectively, in the general population.
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